Tumor Biology

, Volume 37, Issue 1, pp 971–978 | Cite as

Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer

  • Oyeon Cho
  • Young-Taek Oh
  • Mison Chun
  • O Kyu Noh
  • Hyun-Woo Lee
Original Article

Abstract

The purpose of this study was to investigate whether the minimum absolute lymphocyte count during radiotherapy (min ALC) and the absolute lymphocyte count 1 month after radiotherapy (post ALC) could predict clinical outcome in limited-stage small cell lung cancer (LS-SCLC) patients. We analyzed 73 LS-SCLC patients treated with chemotherapy and radiotherapy; we collected data on the min ALC from 62 patients and on the post ALC from 60 patients. Both min ALC and post ALC were statistically significant predictors of overall survival in multivariate analysis (hazard ratio [95 % confidence interval] 2.67 [1.06–6.75], P = 0.038 and 2.62 [1.19–5.74], P = 0.016, respectively). The median overall survival of the patients with min ALC ≤297 and >297 cells/μL was 12.2 and 35.3 months, respectively (P < 0.001). Patients with post ALC ≤698 and >698 cells/μL had an overall survival of 19.3 and 46.9 months, respectively (P = 0.001). The median overall survival of the lymphopenia (min ALC ≤ 297 cells/μL or post ALC ≤ 698 cells/μL) and the non-lymphopenia group (min ALC > 297 cells/μL and post ALC > 698 cells/μL) was 19.0 and 131.7 months, respectively, while the median progression survival was 8.1 and 16.6 months, respectively (P < 0.001 and P = 0.001). Radiation-related lymphopenia could predict poor survival in LS-SCLC. Its prognostic role should be evaluated in further prospective studies.

Keywords

Limited-stage small cell lung cancer Lymphopenia Radiotherapy Survival 

Abbreviations

Min ALC

Minimum absolute lymphocyte count during radiotherapy

Post ALC

The absolute lymphocyte count 1 month after radiotherapy

RRL

Radiation-related lymphopenia

Notes

Acknowledgments

The authors thank all staffs related to the treatment and all the patients suffering from small cell lung cancer.

Conflicts of interest

None

Supplementary material

13277_2015_3888_MOESM1_ESM.pdf (75 kb)
Online Resource 1 (a) The available gross tumor volumes and linear regression analysis of the 59 patients plotted against the min ALCs (b) Pearson correlation coefficients between gross tumor volume, total radiotherapy dose, and radiotherapy duration and the min ALCs or post ALCs (PDF 74 kb)
13277_2015_3888_MOESM2_ESM.pdf (480 kb)
Online Resource 2 The available white blood cell count and the relative tie lines for each of the 56 patients (a) and 6 patients (b) treated with concurrent or alternate CRT and sequential CRT plotted against the radiation days. The available absolute neutrophil counts and the relative tie lines for each of the 56 patients (c) and 6 patients (d) treated with concurrent or alternate CRT and sequential CRT plotted against the radiation days (PDF 480 kb)
13277_2015_3888_MOESM3_ESM.docx (14 kb)
Online Resource 3 (DOCX 14 kb)
13277_2015_3888_MOESM4_ESM.docx (14 kb)
Online Resource 4 (DOCX 14 kb)

References

  1. 1.
    Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, International Staging C, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the tnm classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2008;3:457–66.Google Scholar
  2. 2.
    Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J. 2001;7:437–47.PubMedGoogle Scholar
  3. 3.
    Hermes A, Gatzemeier U, Waschki B, Reck M. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer—a retrospective single institution analysis. Respir Med. 2010;104:1937–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.CrossRefPubMedGoogle Scholar
  6. 6.
    Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111:452–60.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 2000;48:997–1006.CrossRefPubMedGoogle Scholar
  8. 8.
    Lissoni P, Meregalli S, Bonetto E, Mancuso M, Brivio F, Colciago M, et al. Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms. J Biol Regul Homeost Agents. 2005;19:153–8.PubMedGoogle Scholar
  9. 9.
    Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Investig. 2013;31:183–8.CrossRefGoogle Scholar
  10. 10.
    Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Investig. 2012;30:571–6.CrossRefGoogle Scholar
  11. 11.
    Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73–85.CrossRefGoogle Scholar
  12. 12.
    Hothorn T, Lausen B. Maximally selected rank statistics in r. R News. 2002;2:3–5.Google Scholar
  13. 13.
    Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol. 2012;1:149–54.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zachariah B, Jacob SS, Gwede C, Cantor A, Patil J, Casey L, et al. Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. Int J Radiat Oncol Biol Phys. 2001;50:465–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Hu P, Pang Z, Shen H, Wang G, Sun H, Du J. Tumor-infiltrating neutrophils predict poor outcome in adenocarcinoma of the esophagogastric junction. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015;36:2965–71.CrossRefGoogle Scholar
  17. 17.
    Kawada T. Smoking-induced leukocytosis can persist after cessation of smoking. Arch Med Res. 2004;35:246–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Boxer LA, Allen JM, Baehner RL. Diminished polymorphonuclear leukocyte adherence. Function dependent on release of cyclic amp by endothelial cells after stimulation of beta-receptors by epinephrine. J Clin Invest. 1980;66:268–74.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–37.CrossRefPubMedGoogle Scholar
  20. 20.
    Blay J, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11:55–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Heo J, Chun M, Noh OK, Oh YT, Suh KW, Park JE, Cho O: Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer. Cancer research and treatment : official journal of Korean Cancer Association 2015Google Scholar
  23. 23.
    Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14:821–8.CrossRefGoogle Scholar
  24. 24.
    Ceze N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 2011;68:1305–13.CrossRefPubMedGoogle Scholar
  25. 25.
    Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.CrossRefPubMedGoogle Scholar
  26. 26.
    Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.CrossRefPubMedGoogle Scholar
  28. 28.
    Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11:336–44.CrossRefGoogle Scholar
  29. 29.
    Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:3054–60.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Oyeon Cho
    • 1
  • Young-Taek Oh
    • 1
  • Mison Chun
    • 1
  • O Kyu Noh
    • 1
  • Hyun-Woo Lee
    • 2
  1. 1.Department of Radiation OncologyAjou University School of MedicineSuwonRepublic of Korea
  2. 2.Department of Hematology and Medical OncologyAjou University School of MedicineSuwonRepublic of Korea

Personalised recommendations